Trial Condition(s):
Chronic Bronchitis
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB) (SYMPROVE III)
Bayer Identifier:
12629
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.
Inclusion Criteria
- Acute exacerbation of chronic bronchitis from Anthonisen type I or II - FEV1 of < 50 % - Patient must be ensured in the statutory health insurance - Further contraindications of the prescribed pharmaceutical products must be considered
Exclusion Criteria
- Patients who change from one cohort to the other
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Effectiveness and tolerance of/to the different therapiesTimeframe: within the first 14 days
- Possible hospitalisation rateTimeframe: within the first 14 days
Additional Information
Copyright © Bayer
Powered by
